OPK · OPKO Health, Inc.

OPKO Health’s Q1 2026 results reflect a strategic transition following the September 2025 divestiture of its oncology diagnostics assets to Labcorp, which materially reshaped both revenue composition and cost structure. Consolidated revenue declined 17% year-over-year to $124.2 million, but this was expected and largely attributable to the $25.9 million in divested diagnostics revenue — not organic weakness. Diagnostics services revenue fell to $72.2 million, while pharmaceutical revenue grew 9% to $38.0 million, supported by international volume gains and favorable foreign exchange, though offset partially by reduced BARDA contract revenue ($4.1M vs $7.0M). The $16.2 million improvement in operating loss (to $51.0M) reflects both lower fixed costs post-divestiture and disciplined R&D allocation, with R&D expense embedded in total costs and expenses. Notably, gross profit share from NGENLA rose 42% to $6.4 million, signaling continued commercial traction for OPKO’s partnered assets. Management reaffirmed full-year revenue guidance of $530–560 million and introduced Q2-specific ranges, indicating confidence in near-term execution. The $341.9 million in cash and equivalents provides substantial runway to advance multiple late-preclinical and early-clinical assets — including MDX2301 (Phase 1 completed), MDX2003 (Phase 1 initiated), and the Entera oral PTH program (IND expected late 2026) — without immediate financing pressure. While EPS improved to ($0.07), the absolute loss remains significant, underscoring that near-term value hinges on clinical milestones and partnership execution rather than profitability.